- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Anti-Aging
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
K-beauty brand BIOTOC launches in U.S.
BIOTOC, a noninvasive alternative to injectables skincare line from k-beauty company Dermafirm Inc., has launched in the U.S.
Dermafirm USA Inc., announced the U.S. launch of their prestige skincare line, BIOTOC. The brand is a professional grade, anti-aging facial treatment and noninvasive alternative to injectables, according to a company statement.
The product line was initially planned to be distributed via the business-to-business (B2B) channel; however, the company shifted to marketing direct-to-consumer (D2C), citing the consumer interest in the self-care trend due to the COVID-19 pandemic.
"BIOTOC offers visible results, as a topical alternative to injectables that can be applied at home. Given the business reality of increased consumer demand for safe, natural and effective DIY products, and the unknown of when businesses would re-open, we evolved our strategy. We repositioned our new prestige skincare line's direction adding D2C and haven't looked back," says Paula Park, CEO and founder of Dermafirm USA.
MORE: Evidence Skincare offers complementary skin surveys
BIOTOC 3X incorporates astaxanthin mixed with hyaluronic acid, three peptides, collagen hydrolysates and ceramide, the company says. Astaxanthin is an antioxidant that is 6,000 times more potent than vitamin C, 800 times more powerful than CoQ10, 550 times stronger than vitamin E, 75 times more potent that alpha lipoic acid and 40 times more powerful than beta-carotene, the company notes.
In clinical studies, the skincare line resulted in an increase in the skin’s energy production. In addition, it brightened and restored skin elasticity, as well as improved the appearance of fine lines and wrinkles, according to the Dermafirm USA, a branch of South Korea-based cosmeceutical company Dermafirm Inc.
More information can be found at www.dermafirmusa.com.
References:
USA, D. (2020, August 05). COVID-19 Impetus for New D2C Biotech-Based Skincare Solution That Rivals Injectables. Retrieved August 19, 2020, from https://www.prnewswire.com/news-releases/covid-19-impetus-for-new-d2c-biotech-based-skincare-solution-that-rivals-injectables-301106614.html
